J Infect Dis . Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch

[tetano]

J Infect Dis


. 2022 Sep 17;jiac346.
doi: 10.1093/infdis/jiac346. Online ahead of print.
Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch


Raymund R Razonable ¹ , John C O'Horo ¹ , Sara N Hanson ² , Richard F Arndt ³ , Leigh L Speicher ⁴ , Teresa A Seville ⁵ , Scott T Hall ⁶ , Marsha L Pike ¹ , Alexander Heyliger ¹ , Jennifer J Larsen ¹ , Ravindra Ganesh ¹ , Sidna M Tulledge-Scheitel ¹



Affiliations

• PMID: 36124696
• DOI: 10.1093/infdis/jiac346

Abstract

The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3,607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of COVID-19 among older patients, immunosuppressed patients, and those with multiple comorbidities. Despite its use in highly comorbid patients, the rates of progression to severe disease after bebtelovimab (1.4%; 95% confidence interval: 1.2, 1.7) was not significantly different from nirmatrelvir-ritonavir treatment (1.2%; 95% confidence interval: 0.8, 1.5). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.

Keywords: SARS-CoV-2; bebtelovimab; covid-19; hospitalization; monoclonal antibodies; nirmatrelvir; paxlovid; ritonavir.